ClinicalTrials.gg
CompletedNCT02412852Updated Apr 24, 2020Results posted

A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain

A Phase 2 interventional study of Sodium nitrite and Placebo in Diabetes, sponsored by TheraVasc Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by TheraVasc Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,022 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 389 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Enrollment
1,905th of 2,501
26 · median 82
Started
2015
with 106 others
Phase 2
279 of 3,022
16 open now
Registered
1,772nd of 3,022
by date

Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 1,905th largest by enrollment of the 2,501 interventional ones that give a count, is one of 107 that started in 2015, is one of 279 in phase 2, and was the 1,772nd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,022 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

In this study, subjects with diabetic neuropathic pain (DNP) will be treated for 12 weeks with either placebo, 40 or 80 mg sustained release sodium nitrite (TV1001sr) twice daily. Primary endpoints will be safety and pharmacokinetics. Assessment of the study medications affects on pain following treatment will also be recorded.

Read the detailed description

This is a dose-ranging study to evaluate the safety, pharmacokinetics, and tolerability of multiple doses of an oral, sustained release formulation of sodium nitrite (TV1001sr) in subjects with DNP. The primary objective is to assess the safety and tolerability of multiple doses of twice daily 40 mg and 80 mg TV1001sr compared with placebo over a 12 week treatment period and the pharmacokinetics of the sustained release formulation of sodium nitrite. Secondary objectives are to evaluate the pharmacokinetics and markers of functional improvement including pain questionnaires, quantitative sensory testing and changes in markers of diabetes.

03

Conditions studied

  • Diabetes

Browse trials for

Keywords

  • neuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects must be , sterilized or using suitable
  • Diagnosis of diabetes ( > 6.0)
  • Diagnosis of diabetic peripheral neuropathy pain in feet
  • Presence of ongoing diabetic neuropathic for at least 3 months
  • A pain score of greater than or equal to 4 on the Numerical Pain Rating Scale at screening
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Patients with fibromyalgia or regional pain caused by lumbar or cervical compression
  • History or diagnosis of significant neurological disease
  • History and diagnosis of psychiatric diseases
  • Serious liver disease
  • Poorly controlled diabetes
  • to sodium nitrite or related compounds
  • \< 6 months
  • A chronic illness that may increase the risks associated with this study
  • Active requiring active anti-neoplastic therapy that will, in the opinion of the investigator, interfere with study treatment or participation
  • Pregnant or nursing women
  • Current diagnosis of alcohol or other substance abuse
  • Current use of sildenafil or other phosphodiesterase Type 5 Inhibitors
  • History of methemoglobinemia, (met- ≥ 15%)
  • Subject is involved in litigation or receives worker's compensation
  • Inability to speak English
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    One placebo tablet administered twice daily for 12 weeks.

    Drug: Placebo

  • Active comparator
    40 mg TV1001sr

    One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.

    Drug: Sodium nitrite

  • Placebo comparator
    Placebo (2)

    Two placebo tablets administered twice daily for 12 weeks.

    Drug: Placebo

  • Active comparator
    80 mg TV1001sr

    Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.

    Drug: Sodium nitrite

Interventions

  • Sustained release formulation of sodium nitrite

    Also known as: TV1001sr

  • DrugPlacebo

    Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.

06

What researchers measure

Primary outcomes

  1. Reporting of Adverse Events During 12 Week Study Period

    The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sustained release sodium nitrite compared with placebo over a 12 week treatment period. The following safety parameters will also be assessed: concomitant medication usage, physical examination, vital signs, Comprehensive Metabolic Panel, and complete blood count. Assessment of acute adverse events (i.e., drop in blood pressure, dizziness) after administration of each dose level. Counts are number of subjects reporting at least 1 Adverse Event. The total Adverse Events recorded in each cohort is also reported.

    Time frame: 12 weeks

Secondary outcomes

  1. Pharmacokinetics (Blood Levels of Nitrite)

    Blood levels of nitrite will be assessed for 6 hours post-administration on the initial dosing visit.

    Time frame: 1 day

  2. The Number of Participants Who Reported Use of Analgesic or Medications for Neuropathic Pain.

    Daily patient reported use of analgesic or medications for neuropathic pain. The use of medications were recorded at the baseline visit and during both the intermediate and final visit for each subject. All subjects used at least one prescription pain medication, other than one subject in the 80-mg dose cohort who used only ibuprofen to control pain. Most subjects used more than one prescription pain medication. There was no change in use of pain medications during the trial period.

    Time frame: 12 weeks

  3. Assessment of Patients Reported Pain Through Composite Analysis of Pain Questionaires.

    Subjects completed the Brief pain inventory (BPI), RAND 36 questionnaire, neuropathic pain symptom inventory (NPSI) and Short Form McGill Pain Questionnaire at each visit for these self-reported questionnaires. The BPI is a questionnaire that measures the patient's subjective perception of pain, its exacerbating and alleviating factors, and perceived effect on functional status; the NPSI is a questionnaire that measures the symptoms associated with neuropathic pain; the Short Form McGill Questionnaire subjectively assesses the patients perception of pain described by commonly used adjectives associated with pain. NPSI is average of 12 questions, range from 0 (no pain) to 120 (maximal pain); For BPI severity and interference, questions are scored from 0-10, then there average score for each subsection is calculated (the higher the score, the worse the response); Scores on McGill range from 0-10, lower associated for less pain, then averaged for each sub score and total score.

    Time frame: Baseline (visit 1) and 12 weeks (visit 3)

  4. Clinical Assessment of Pain. (Quantitative Sensory Testing)

    Quantitative sensory testing (QST) was conducted at each visit to determine patients sensitivity to pain. QST was assessed using a quantitative nerve conductance machine where nerves in the distal extremity are subjected to electrical stimulation to determine the sensory threshold of the skin. Nerve conductance measures how fast an electrical impulse moves through the nerve, and nerve velocity measures the speed at which an electrical impulse moves down a neuronal pathway.

    Time frame: 12 weeks

  5. Assessment of Diabetes. (HbA1C Levels)

    HbA1C levels will be monitored at each visit to determine whether treatment reduces circulating glucose levels.

    Time frame: 12 weeks

  6. Assessment of Blood Oxygenation. (Pulse Oximetry)

    Pulse oximetry will be used at each visit to determine whether treatment improves oxygen levels in the blood.

    Time frame: 12 weeks

07

Results

Posted Apr 24, 2020

Participant flow

Participant flow — Overall Study
MilestonePlacebo40 mg TV1001srPlacebo (2)80 mg TV1001sr
Started4859
Completed4758
Not completed0101
Withdrew: Withdrawal by subject0100
Withdrew: Physician decision0001

Outcome measures

PrimaryReporting of Adverse Events During 12 Week Study Period

The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sustained release sodium nitrite compared with placebo over a 12 week treatment period. The following safety parameters will also be assessed: concomitant medication usage, physical examination, vital signs, Comprehensive Metabolic Panel, and complete blood count. Assessment of acute adverse events (i.e., drop in blood pressure, dizziness) after administration of each dose level. Counts are number of subjects reporting at least 1 Adverse Event. The total Adverse Events recorded in each cohort is also reported.

Time frame:
12 weeks
Reported as:
Number · Adverse Events
Reporting of Adverse Events During 12 Week Study Period
Adverse EventsCombined Placebo40 mg TV1001sr80 mg TV1001sr
Subjects reporting at least one Adverse Event987
Total Adverse Events reported in each cohort292324
SecondaryPharmacokinetics (Blood Levels of Nitrite)

Blood levels of nitrite will be assessed for 6 hours post-administration on the initial dosing visit.

Time frame:
1 day
Reported as:
Mean · ng/ml
Pharmacokinetics (Blood Levels of Nitrite)
ng/mlCombined Placebo40 mg TV1001sr80 mg TV1001sr
Pharmacokinetics (Blood Levels of Nitrite)1399 ± 479699 ± 101999905 ± 12383
Statistical analysis
  • Combined Placebo vs 40 mg TV1001sr vs 80 mg TV1001sr ·
SecondaryThe Number of Participants Who Reported Use of Analgesic or Medications for Neuropathic Pain.

Daily patient reported use of analgesic or medications for neuropathic pain. The use of medications were recorded at the baseline visit and during both the intermediate and final visit for each subject. All subjects used at least one prescription pain medication, other than one subject in the 80-mg dose cohort who used only ibuprofen to control pain. Most subjects used more than one prescription pain medication. There was no change in use of pain medications during the trial period.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
The Number of Participants Who Reported Use of Analgesic or Medications for Neuropathic Pain.
ParticipantsCombined Placebo40 mg TV1001sr80 mg TV1001sr
Subjects using any medicine to treat pain978
Subjects using Gabapentin663
Subjects using Lyrica444
Subjects using Morphine210
Subjects using Tramadol133
Subjects using Cymbalta112
Subjects using Flexeril102
Subjects using Naproxen130
Subjects using Percocet310
Subjects using Vicodin221
SecondaryAssessment of Patients Reported Pain Through Composite Analysis of Pain Questionaires.

Subjects completed the Brief pain inventory (BPI), RAND 36 questionnaire, neuropathic pain symptom inventory (NPSI) and Short Form McGill Pain Questionnaire at each visit for these self-reported questionnaires. The BPI is a questionnaire that measures the patient's subjective perception of pain, its exacerbating and alleviating factors, and perceived effect on functional status; the NPSI is a questionnaire that measures the symptoms associated with neuropathic pain; the Short Form McGill Questionnaire subjectively assesses the patients perception of pain described by commonly used adjectives associated with pain. NPSI is average of 12 questions, range from 0 (no pain) to 120 (maximal pain); For BPI severity and interference, questions are scored from 0-10, then there average score for each subsection is calculated (the higher the score, the worse the response); Scores on McGill range from 0-10, lower associated for less pain, then averaged for each sub score and total score.

Time frame:
Baseline (visit 1) and 12 weeks (visit 3)
Reported as:
Mean · units on a scale
Assessment of Patients Reported Pain Through Composite Analysis of Pain Questionaires.
units on a scaleCombined Placebo40 mg TV1001sr80 mg TV1001sr
NPSI: Total-V147.4 (7 to 75)34.7 (18 to 80)56.0 (21 to 83)
NPSI: Total-V343.4 (9 to 81)30.0 (0 to 76)46.0 (6 to 73)
BPI: Severity Score-V15.1 (1.25 to 7.5)4.3 (1.25 to 8.5)5.9 (2.5 to 9.3)
BPI: Severity Score-V34.8 (1.5 to 7.8)3.8 (0.8 to 8.8)5.1 (2.0 to 8.3)
BPI: Interferrence-V15.0 (0.0 to 9.7)4.4 (0.7 to 7.9)6.4 (2.0 to 8.5)
BPI: Interferrence-V34.3 (0.0 to 10.0)4.2 (1.1 to 8.6)5.7 (3.1 to 8.9)
McGill: Total-V15.1 (1.1 to 9.1)3.9 (1.8 to 7.6)4.8 (1.7 to 7.9)
McGill: Total-V33.6 (0.4 to 7.5)2.5 (0.5 to 7.2)4.6 (0.5 to 7.0)
McGill: Continuous-V15.0 (1.0 to 9.0)3.7 (0.9 to 7.2)4.4 (0.5 to 8.0)
McGill: Continuous-V33.2 (0.0 to 6.6)1.9 (0.0 to 5.8)4.3 (0.7 to 7.5)
McGill: Intermittent-V16.0 (0.0 to 9.7)4.6 (2.3 to 8.5)5.9 (0.3 to 8.0)
McGill: Intermittent-V34.1 (0.0 to 9.2)2.8 (0.0 to 8.3)5.3 (0.0 to 7.3)
Statistical analysis
  • Combined Placebo vs 40 mg TV1001sr vs 80 mg TV1001sr · ANOVA · p = 0.05 (The results were analyzed using an ANOVA with one between-subjects factor (Group: both placebo groups combined, 40 mg TV1001sr, and 80 mg TV1001sr); and one within-subjects factor (Visit: Visit 1, Visit 2, and Visit 3).)The means of the three groups were further analyzed using a post hoc comparison procedure (the Scheffé test).
SecondaryClinical Assessment of Pain. (Quantitative Sensory Testing)

Quantitative sensory testing (QST) was conducted at each visit to determine patients sensitivity to pain. QST was assessed using a quantitative nerve conductance machine where nerves in the distal extremity are subjected to electrical stimulation to determine the sensory threshold of the skin. Nerve conductance measures how fast an electrical impulse moves through the nerve, and nerve velocity measures the speed at which an electrical impulse moves down a neuronal pathway.

Time frame:
12 weeks
Reported as:
Mean · meters per second
Clinical Assessment of Pain. (Quantitative Sensory Testing)
meters per secondCombined Placebo40 mg TV1001sr80 mg TV1001sr
Nerve Conductance: Baseline3.9 ± 1.43.4 ± 0.76.0 ± 2.9
Nerve Conductance: V24.3 ± 1.83.1 ± 0.95.2 ± 3.0
Nerve Conductance: V33.5 ± 1.23.2 ± 0.64.2 ± 1.5
Nerve Velocity: Baseline44.7 ± 6.541.1 ± 4.339.4 ± 8.2
Nerve Velocity: V240.1 ± 5.339.3 ± 7.842.3 ± 10.7
Nerve Velocity: V343.2 ± 6.437.7 ± 3.246.8 ± 4.2
Statistical analysis
  • Combined Placebo vs 40 mg TV1001sr vs 80 mg TV1001sr · ANOVA · p = .15
SecondaryAssessment of Diabetes. (HbA1C Levels)

HbA1C levels will be monitored at each visit to determine whether treatment reduces circulating glucose levels.

Time frame:
12 weeks
Reported as:
Mean · percentage of glycosylated hemoglobin
Assessment of Diabetes. (HbA1C Levels)
percentage of glycosylated hemoglobinCombined Placebo40 mg TV1001sr80 mg TV1001sr
Baseline7.7 ± 1.47.7 ± 1.28.5 ± 2.4
V27.3 ± 1.27.4 ± 0.97.9 ± 1.8
V37.6 ± 2.07.7 ± 1.68.2 ± 1.2
Statistical analysis
  • Combined Placebo vs 40 mg TV1001sr vs 80 mg TV1001sr · ANOVA · p = .36
SecondaryAssessment of Blood Oxygenation. (Pulse Oximetry)

Pulse oximetry will be used at each visit to determine whether treatment improves oxygen levels in the blood.

Time frame:
12 weeks
Reported as:
Mean · % Oxygenation
Assessment of Blood Oxygenation. (Pulse Oximetry)
% OxygenationCombined Placebo40 mg TV1001sr80 mg TV1001sr
Baseline95.7 ± 2.695.6 ± 2.396.3 ± 1.7
V296.0 ± 3.096.4 ± 2.295.3 ± 3.2
V394.2 ± 2.896.0 ± 2.495.1 ± 2.4
Statistical analysis
  • Combined Placebo vs 40 mg TV1001sr vs 80 mg TV1001sr · ANOVA · p = .93

Adverse events

Collected over 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combined Placebo0/9 (0%)2/9 (22.2%)9/9 (100%)
40 mg TV1001sr0/8 (0%)2/8 (25%)8/8 (100%)
80 mg TV1001sr0/9 (0%)2/8 (25%)7/9 (77.8%)
Most frequent serious events
Most frequent serious events
EventCombined Placebo40 mg TV1001sr80 mg TV1001sr
HyponatremiaBlood and lymphatic system disorders0/91/81/8
HyperglycemiaBlood and lymphatic system disorders1/91/80/8
Febrile illnessInfections and infestations0/90/81/8
Chest painsCardiac disorders1/90/80/8
Most frequent other events
Most frequent other events
EventCombined Placebo40 mg TV1001sr80 mg TV1001sr
SwellingGeneral disorders4/90/81/9
Urinary DisordersRenal and urinary disorders1/93/81/9
DizzinessNervous system disorders2/92/82/9
ConstipationGastrointestinal disorders0/92/80/9
HeadachesNervous system disorders2/90/82/9
NumbnessNervous system disorders2/90/80/9
UlcersGastrointestinal disorders0/91/81/9
FatigueNervous system disorders1/91/80/9
Dry MouthGeneral disorders0/91/81/9
NauseaGastrointestinal disorders1/91/80/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo40 mg TV1001srPlacebo (2)80 mg TV1001srTotal
<=18 years00000
Between 18 and 65 years162716
>=65 years323210
Sex: Female, Male
Sex: Female, Male(Participants)Placebo40 mg TV1001srPlacebo (2)80 mg TV1001srTotal
Female034512
Male451414
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo40 mg TV1001srPlacebo (2)80 mg TV1001srTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White485926
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Placebo40 mg TV1001srPlacebo (2)80 mg TV1001srTotal
United States485926
08

Study locations

1 site
  • Ohio Pain Clinic
    Centerville, Ohio 45458, United States
09

References and documents

Individual participant data

Plan to share: No — IPD will only be available to the PI of the trial, summary information will be published and shared with other researchers.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Dec 2015, 7 months.

Results were first posted in Apr 2020, 4 years 4 months after primary completion.

Of 65 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 7 months is below that.

Counting every sponsor, half of 147 studies reached it within 27 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2015
First posted
Apr 9, 2015
StartActual
Apr 28, 2015
Primary completionActual
Dec 7, 2015
CompletionActual
Apr 3, 2017
Results first posted
Apr 24, 2020
Last update
Apr 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02412852
Lead sponsor
TheraVasc Inc.
Collaborators
Kettering Health Network
Responsible party
Sponsor
First posted
Apr 9, 2015
Start date
Apr 28, 2015
Primary completion
Dec 7, 2015
Completion
Apr 3, 2017
Results posted
Apr 24, 2020
Last update
Apr 24, 2020

Study contacts

Amol Soin, PhD
principal investigator · Ohio Pain Clinic

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Nitrite

Start the discussion